These include SLC45A3-ELK4, MSMB-NCOA4, D2HGDH-GAL3ST2, and DUS4L-BCAP29 in prostate cancer [18,24,37,38,39], SCNN1A-TNFRSF1A and CTSD-IFITM10 in breast cancer [40], LHX6-NDUFA8 and SLC2A11-MIF in cervical cancer [41], BCL2L2-PABPN1, HNRNPA1L2-SUGT1 and CHFR-GOLGA3 in bladder cancer [42,43], RRM2-C2orf48, METTL21B-TSFM, SF3A2-AMH, and TMEM189-UBE2V1 in colorectal cancer [44,45], CTSC-RAB38, KDSR-BCL2, and KLK4-KRSP1 in kidney cancer [7,46], BCL2L2-PABPN1 in glioblastoma [47], etc. (Table 1). Here, SUGT1 is linked to urinary bladder carcinoma.